John Bisognano, MD
Enriched profileClinical Professor of Internal Medicine and Interim Chief, Division of Cardiovascular Medicine · University of Michigan
John Bisognano is Clinical Professor of Internal Medicine and Interim Chief, Division of Cardiovascular Medicine at University of Michigan. OpenAlex indexes 161 publications with 5,880 citations (h-index 29); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
John Bisognano, MD, is Clinical Professor of Internal Medicine and Interim Chief, Division of Cardiovascular Medicine at University of Michigan. The public record shows 161 publications with 5,880 citations (h-index 29), centered on Blood Pressure and Hypertension Studies, Cardiovascular Syncope and Autonomic Disorders, Heart Rate Variability and Autonomic Control. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 8 companies.
- Most recent indexed publication: 2020 · Journal of human hypertension
- Top research focus: Blood Pressure and Hypertension Studies
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 65.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Conditioned Pharmacotherapeutic Effects in Hypertension
Sponsor: University of Rochester
Industry payments
Updated 16 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Kestra Medical Technology Services, Inc.Program year20251 payment
- Abbott LaboratoriesProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
91.6%Statin20.7%Atorvastatin Calcium55%Rosuvastatin Calcium41%Pravastatin Sodium5%Part D<11 patientsPCSK9 Inhibitor14.4%Repatha Sureclick74%Praluent Pen23%Repatha Syringe4%Part D<11 patients+ 14 more classes in this area
Blood & clotting
6.7%Factor Xa inhibitor6%Eliquis72%Xarelto28%Part D≥34 patientsP2Y12 inhibitor0.7%Clopidogrel100%Part D<11 patientsMetabolism & gastrointestinal
1.2%Potassium supplement0.8%Potassium Chloride100%Part D<11 patientsProton pump inhibitor0.4%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Reducing cardiovascular risk caused by air pollution: individuals can make a difference.
Journal of human hypertension
Comment2020
Most-cited works
by citation count (OpenAlex)- 01Clinical Practice Guidelines for the Management of Hypertension in the CommunityArticle988 citations2013
- 02Clinical Practice Guidelines for the Management of Hypertension in the CommunityArticle684 citations2013
- 03Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant HypertensionArticle600 citations2011
- 04Beyond Medications and Diet: Alternative Approaches to Lowering Blood PressureArticle573 citations2013
- 05Myocardial-Directed Overexpression of the Human β1-Adrenergic Receptor in Transgenic MiceArticle265 citations2000
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/john-bisognano-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
SUNY Upstate Medical University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗ - PhD in physical chemistry
SUNY Binghamton
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗
Editorial & leadership roles
journal and society appointments- President
American Society of Hypertension
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cardiovascularbusiness.com ↗ - Vice-Chair
American Heart Association Council on High Blood Pressure
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sma.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urmc.rochester.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urmc.rochester.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urmc.rochester.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urmc.rochester.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Paul Ridker, MD
Brigham and Women's Hospital
Edward Giovannucci, MD, ScD, MPH
Harvard T.H. Chan School of Public Health
Stephen Chanock, MD
National Cancer Institute (NCI)
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center